Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIIb Multicenter, Double-blind, Placebo-controlled,Randomized Trial to Examine the Corticosteroid-sparing Effect of Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease.

NCT00349752 is registered in ClinicalTrials.gov with UCB Pharma as lead sponsor.

NCT NCT00349752
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00349752 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIIb Multicenter, Double-blind, Placebo-controlled,Randomized Trial to Examine the Corticosteroid-sparing Effect of Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease.
Lead sponsor
UCB Pharma
Phase
Phase 3
Overall status
Terminated
Start date
November 30, 2006
Completion date
July 31, 2009
Enrollment
174 (actual)
Sites
68

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease